Tocopherol is a Novel Treatment for Cancer Related Mucositis
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The present protocol is an attempt to prevent/treat mucositis in highly susceptible patients
subjected to maximally tolerated doses of subsequently-myeloablative or myeloablative doses
of chemoradiotherapy supported by autologous or allogeneic stem cell transplantation at the
Department of Bone Marrow Transplantation. Mucositis is a major problem in the management of
transplant recipients which subjects the patients to the risk of sepsis, need for parenteral
nutrition and need of narcotics. We are planning a 2 arm study, comparing 2 safe vitamin E
based formulations with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Hadassah Medical Organization
Treatments:
alpha-Tocopherol Tocopherols Tocotrienols Vitamin E